CN1357330A - Externally-applied medicine for treating dermatosis - Google Patents
Externally-applied medicine for treating dermatosis Download PDFInfo
- Publication number
- CN1357330A CN1357330A CN 01131820 CN01131820A CN1357330A CN 1357330 A CN1357330 A CN 1357330A CN 01131820 CN01131820 CN 01131820 CN 01131820 A CN01131820 A CN 01131820A CN 1357330 A CN1357330 A CN 1357330A
- Authority
- CN
- China
- Prior art keywords
- liquid
- substrate
- dexamethasone
- water
- dyclonine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The externally applied medicine for treating dermatosis is prepared by mixing the water phase components including urea, dodecyl sodium sulfate, Dyclonine and Tween-80, heating to melt and maintaining at 80 deg.c; mixing the oil phase components including stearic acid, napagin A, liquid paraffin, Vaseline and span-80, heating to melt and maintaining at 80 deg.c; adding the oil phase into the water phase slowly while stirring to make the substrate; adding the dimethyl sulfoxide solution of Dexamethasone slowly while stirring to the substrate cooled to below 60 deg.C and liquefying camphor with phenol and adding it to the cooled substrate while stirring. It has high treating effect on acute and chronic dermatosis.
Description
The present invention relates to the dermopathic external used medicine of a kind of treatment.
At present, people are in treatment during dermatosis, the most frequently used external used medicine as: Piyanping ointment, this medicine are by dexamethasone acetate 0.75, Camphora 10.0, Oleum menthae 10.0, substrate add to 1000 formations such as grade, are mainly used in various eczema, dermatitis, skin acropathies such as pruritus, its utilization scope is wide, and sales volume is big to be that other dermatosis treating medicines institute can not reach.But a large amount of clinical practices prove that this medical instrument has following shortcoming: 1, better to the sick effect of acute skin, to chronic disease difference even invalid; 2, antipruritic effect is not good, many patients with after still pruritus scratch and do not stop unbearably, influence therapeutic effect; 3, be easy to recurrence after the drug withdrawal.
The purpose of this invention is to provide a kind of dermopathic external used medicine of a kind of treatment that acute and chronic dermatosis is all had better curative effect.
The technical scheme that realizes the object of the invention is as follows,
A), choose following consumption and take by weighing raw material,
Dyclonine 5～15g, Camphora 50～80g, dexamethasone 0.2～1.0g,
Carbamide 60～120g, stearic acid 200g, liquid paraffin 100g,
Vaseline 50g, sodium lauryl sulphate 10g, dimethyl sulfoxide 60～100g,
Ethyl hydroxybenzoate 1g, Arlacel-80 20g, tween 80 30g,
Phenol is an amount of, distilled water 450～500g
B), compound method:
Dexamethasone is dissolved in the dimethyl sulfoxide,
The water intaking phase constituent: carbamide, sodium lauryl sulphate, dyclonine, tween 80, itself and distilled water Hybrid Heating are fused into water liquid, and keep 80 ℃ of temperature,
Get oil-phase component: stearic acid, ethyl hydroxybenzoate, liquid paraffin, vaseline, Arlacel-80, its Hybrid Heating is fused into oil phase liquid, and keeps 80 ℃ of temperature,
Above-mentioned oil phase liquid is added in the water liquid slowly, constantly is stirred to typing, with it as substrate,
Dimethyl sulphoxide liquid with dexamethasone under agitation slowly adds in the substrate that is cooled to below 60 ℃ again, and Camphora can add phenol liquefaction, adds at last in the chilled substrate, constantly stirs promptly.
By a large amount of clinical practices, the present invention not only has better therapeutic effect to acute and chronic dermatosis, and antipruritic effect is splendid, and pruritus stops at once after the medication, both alleviated patient's misery, also prevented the skin lesion of scratching and causing simultaneously owing to the patient.With regard to applicant's clinical practice, the single external use medicine for treating dermatosis that is higher than present listing with regard to antipruritic effect of the present invention; And after the regular medication, the state of an illness is difficult for recurrence; Widened the scope of indication.
Below be the present invention to different dermopathic clinical efficacy situations:
Neurodermatitis (cure rate 98%, effective percentage 100%);
Acute eczema (cure rate 97%, effective percentage 100%);
Chronic eczema (cure rate 90%, effective percentage 99%);
Acute urticaria (cure rate 95%, effective percentage 100%);
Chronic urticaria (cure rate 93%, effective percentage 100%);
Various allergic dermatitises (cure rate 94%, effective percentage 99%).
The present invention also has effect preferably to following dermatosis: pompholyx, psoriasis, vitiligo, acne, ichthyosis.
The present invention is described further below in conjunction with embodiment,
Choose following consumption and take by weighing raw material,
Dyclonine 10g, Camphora 60g, dexamethasone 0.6g,
Carbamide 100g, stearic acid 200g, liquid paraffin 100g,
Vaseline 50g, sodium lauryl sulphate 10g, dimethyl sulfoxide 80g,
Ethyl hydroxybenzoate 1g, Arlacel-80 20g, tween 80 30g,
Phenol is an amount of, distilled water 500g.
Compound method:
Dexamethasone is dissolved in the dimethyl sulfoxide,
The water intaking phase constituent: carbamide, sodium lauryl sulphate, dyclonine, tween 80, itself and distilled water Hybrid Heating are melted, and keep 80 ℃ of temperature,
Get oil-phase component: stearic acid, ethyl hydroxybenzoate, liquid paraffin, vaseline, Arlacel-80, with its Hybrid Heating fusing, and keep 80 ℃ of temperature,
Above-mentioned oil phase liquid is added in the water liquid slowly, constantly is stirred to typing, with it as substrate,
Dimethyl sulphoxide liquid with dexamethasone under agitation slowly adds in the substrate that is cooled to below 60 ℃ again, and Camphora can add phenol liquefaction, adds at last in the chilled substrate, constantly stirs promptly.
Part composition role of the present invention:
(1) dyclonine: skin there is pain relieving, antipruritic and bactericidal action, as mucomembranous surface anesthesia, effect is rapid, onset in 2～10 minutes.Be mainly used in antipruritic in the present invention.
(2) Camphora: pruritus, there is the transdermal facilitation in local irritant, can stimulate Cold receptor, and skin is had refrigerant sense, firmly embrocates to promote local blood circulation.Be mainly used in antipruriticly in the present invention, Transdermal absorption allows the people that kind of a refrigerant sense is arranged.
(3) dexamethasone: for synthetic long-acting glucocorticoid, have antiinflammatory, antiallergic, anti rheumatism action.This product easily penetrates tissue, and therefore effect takes place very fast.In invention, be mainly used in antiinflammatory, antiallergic, antipruritic.
(4) carbamide: keatolytics, this product can make the protein dissolving, and degeneration increases proteinic hydration, thereby can strengthen the water content of skin, impels the skin softness.In invention, be mainly used in the treatment chronic dermatosis, improve the cure rate of chronic disease.
(5) dimethyl sulfoxide: this product is an intensive polar solvent, and solubility property is good, and antiinflammatory, pain relieving are arranged, and is antibacterial and promote effect such as wound healing, and in addition, this product can see through horny layer again and at the epidermis internal diffusion.In the present invention, this medicine is mainly used in dissolving dexamethasone and transdermal facilitation.Its stronger transdermal facilitation can impel medicine to enter deep layer, thus the effect that reaches radical cure and prevent to recur.
Claims (1)
1, the dermopathic external used medicine of a kind of treatment is characterized in that,
A), choose following consumption and take by weighing raw material,
Dyclonine 5～15g, Camphora 50～80g, dexamethasone 0.2～1.0g,
Carbamide 60～120g, stearic acid 200g, liquid paraffin 100g,
Vaseline 50g, sodium lauryl sulphate 10g, dimethyl sulfoxide 60～100g,
Ethyl hydroxybenzoate 1g, Arlacel-80 20g, tween 80 30g,
Phenol is an amount of, distilled water 450～500g
B), compound method:
Dexamethasone is dissolved in the dimethyl sulfoxide,
The water intaking phase constituent: carbamide, sodium lauryl sulphate, dyclonine, tween 80, itself and distilled water Hybrid Heating are fused into water liquid, and keep 80 ℃ of temperature,
Get oil-phase component: stearic acid, ethyl hydroxybenzoate, liquid paraffin, vaseline, Arlacel-80, its Hybrid Heating is fused into oil phase liquid, and keeps 80 ℃ of temperature,
Above-mentioned oil phase liquid is added in the water liquid slowly, constantly is stirred to typing, with it as substrate,
Dimethyl sulphoxide liquid with dexamethasone under agitation slowly adds in the substrate that is cooled to below 60 ℃ again, and Camphora can add phenol liquefaction, adds at last in the chilled substrate, constantly stirs promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131820 CN1357330A (en) | 2001-12-03 | 2001-12-03 | Externally-applied medicine for treating dermatosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131820 CN1357330A (en) | 2001-12-03 | 2001-12-03 | Externally-applied medicine for treating dermatosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1357330A true CN1357330A (en) | 2002-07-10 |
Family
ID=4670893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01131820 Pending CN1357330A (en) | 2001-12-03 | 2001-12-03 | Externally-applied medicine for treating dermatosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1357330A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387261C (en) * | 2004-07-27 | 2008-05-14 | 陈卫兵 | Medicnial liquid and technology for one step removing freckle, chloasma and senile plague |
-
2001
- 2001-12-03 CN CN 01131820 patent/CN1357330A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387261C (en) * | 2004-07-27 | 2008-05-14 | 陈卫兵 | Medicnial liquid and technology for one step removing freckle, chloasma and senile plague |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4555524A (en) | Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods | |
| JP2002515401A (en) | Arginine medication with beneficial effects | |
| US7442690B2 (en) | Topical treatment for psoriasis | |
| CN107998107A (en) | A kind of degerming gel of anti-inflammatory containing honey | |
| CN101264070B (en) | Dermatosis-treating medicine and preparation thereof | |
| CN106619823A (en) | Ointment for therapy of eczema and preparation method of same | |
| WO2013007700A1 (en) | Pharmaceutical composition comprising oleic acid, palmitic acid, linoleic acid and linolenic acid | |
| CN1357330A (en) | Externally-applied medicine for treating dermatosis | |
| RU2366432C1 (en) | Therapy of psoriasis | |
| WO2020221347A1 (en) | Compound for treating autoimmune skin diseases caused by inflammation, and use thereof | |
| CN108042654A (en) | A kind of preparation process of the anti-inflammatory degerming gel containing honey | |
| CN1470234A (en) | Capsaicin liposome preparation for skin | |
| CN104510911B (en) | Treat pharmaceutical composition of non-infectious inflammation dermatoses and preparation method thereof | |
| CN1249930A (en) | Diclofenac potassium gel and ointment and the preparation thereof | |
| CN1140276C (en) | Compound chlorhexidine cream and its prepairng method | |
| CN112972391B (en) | bilirubin-JPH 203 nano-particles and preparation and application thereof | |
| CN1255097C (en) | Compound zedoary oil ointment and its preparing method | |
| RU2687485C1 (en) | Agent for therapy of wound and burn skin lesions | |
| CN105769859B (en) | It is a kind of to treat the pharmaceutical composition of skin injury and its application after radiotherapy patients with cervix carcinoma | |
| CN105878427A (en) | Peony seed oil compound spray for curing burn and scald and preparation method | |
| RU2694536C2 (en) | Method for treating skin diseases, burns, superficial and deep wounds | |
| CN1097601A (en) | The medicine and the preparation technology thereof of treatment tinea pedis | |
| WO2006015183A2 (en) | Pharmaceutical compositions for treating disorders of the skin | |
| ITRM990465A1 (en) | PHARMACEUTICAL COMPOSITION BASED ON C2 HCL3O2, A POLYMER H (OCH2CH2) 6OH, 2-HYDROXYDOBENZONIC ACID, (1ALPHA, 2BETA, 5ALPHA) -5-METHYL-2- (1-M | |
| CN113230358A (en) | Cis-15-tetracosenoic acid-containing composition and preparation method of oil agent thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |